| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/02/2011 | US20110129499 Dual delivery system for heterologous antigens |
| 06/02/2011 | US20110129498 Vaccine for the prevention and therapy of hcv infections |
| 06/02/2011 | US20110129497 Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
| 06/02/2011 | US20110129496 Use of mTOR Inhibitors to Enhance T Cell Immune Responses |
| 06/02/2011 | US20110129495 Treatment of prdc in pigs |
| 06/02/2011 | US20110129494 Vaccine Formulations Comprising Saponin-containing Adjuvants |
| 06/02/2011 | US20110129493 Combined measles-human papilloma vacine |
| 06/02/2011 | US20110129492 Immunostimulatory Recombinant Intracellular Pathogen Immunogenic Compositions and Methods of Use |
| 06/02/2011 | US20110129490 Modulation of production of retroviruses by apobec4 |
| 06/02/2011 | US20110129489 Methods for generating an immune response using dna and a viral vector |
| 06/02/2011 | US20110129488 Immunotherapy compositions for the treatment and prevention of amyloidosis |
| 06/02/2011 | US20110129487 Plasmic production and expression of recombinant proteins in cells grown without antibiotics |
| 06/02/2011 | US20110129485 Modified Galectin-2 and Uses Thereof |
| 06/02/2011 | US20110129484 Immunotherapies employing self-assembling vaccines |
| 06/02/2011 | US20110129483 Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| 06/02/2011 | US20110129482 Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| 06/02/2011 | US20110129481 Antibody specifically binding to c-Met and methods of use |
| 06/02/2011 | US20110129480 Anti-ferroportin 1 monoclonal antibodies and uses thereof |
| 06/02/2011 | US20110129479 Immunogen selection directed in immunoglobulin packages in plasma and colostrum and method of making and using same |
| 06/02/2011 | US20110129478 Pharmaceutical composition for treatment and prevention of cancer |
| 06/02/2011 | US20110129477 NOGO Receptor Homologs |
| 06/02/2011 | US20110129476 Mzb1, a novel b cell factor, and uses thereof |
| 06/02/2011 | US20110129475 Basb 205 polypeptides and polynucleotides from haemophilus influenzae |
| 06/02/2011 | US20110129474 Methods And Systems For Multi-Antibody Therapies |
| 06/02/2011 | US20110129473 Vhnar anti-cytokine domains |
| 06/02/2011 | US20110129472 Methods for controlling vasculogenesis |
| 06/02/2011 | US20110129471 Chronic lymphocytic leukemia cell line |
| 06/02/2011 | US20110129470 Use of specifically engineered enzymes to enhance the efficacy of prodrugs |
| 06/02/2011 | US20110129469 Methods for treating fatty liver disease |
| 06/02/2011 | US20110129468 Purified immunoglobulin fusion proteins and methods of their purification |
| 06/02/2011 | US20110129467 Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
| 06/02/2011 | US20110129466 Methods of treating cancer by administering antibodies to cd200 |
| 06/02/2011 | US20110129465 Mammalian Receptor Proteins; Related Reagents and Methods |
| 06/02/2011 | US20110129464 Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
| 06/02/2011 | US20110129463 Quinazolin-4(3A)-One Derivatives and Methods of Use Thereof |
| 06/02/2011 | US20110129462 Intranasal administration of active agents to the central nervous system |
| 06/02/2011 | US20110129461 Mat II Beta Subunit RNAi and Therapeutic Methods Using Same |
| 06/02/2011 | US20110129460 Combination Antibodies For The Treatment And Prevention Of Disease Caused By Bacillus Anthracis And Related Bacteria And Their Toxins |
| 06/02/2011 | US20110129459 Anti-nr10 antibody and use thereof |
| 06/02/2011 | US20110129458 Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| 06/02/2011 | US20110129457 Variant hhip1 protein and methods and uses thereof |
| 06/02/2011 | US20110129456 Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer |
| 06/02/2011 | US20110129455 Inhibitors of akt activity |
| 06/02/2011 | US20110129445 Combinations comprising methotrexate and dhodh inhibitors |
| 06/02/2011 | US20110129441 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients |
| 06/02/2011 | US20110129440 Heterocyclic Urea and Thiourea Derivatives and Methods of Use Thereof |
| 06/02/2011 | US20110129438 Immunogenic protein constructs |
| 06/02/2011 | US20110129422 Viscous Terpolymers as Drug Delivery Platform |
| 06/02/2011 | US20110129416 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| 06/02/2011 | US20110129415 Novel antibody and use in diagnosis and therapy of arthropathies |
| 06/02/2011 | US20110129414 Single Chain Fragment of Monoclonal Antibody 9B9 and Uses Thereof |
| 06/02/2011 | US20110129412 Antibodies Directed to CD20 and Uses Thereof |
| 06/01/2011 | EP2327787A1 Nucleic acids encoding TGEV and PRRSV sequences for improved expression of PRRSV sequences |
| 06/01/2011 | EP2327725A1 Anti-C5a binding moieties with high blocking activity |
| 06/01/2011 | EP2327720A1 Enterococcus antigens |
| 06/01/2011 | EP2327719A1 Hybrid and tandem expression of neisserial proteins |
| 06/01/2011 | EP2327717A1 Replikin peptides and uses thereof |
| 06/01/2011 | EP2327716A1 Replikin peptides and uses thereof |
| 06/01/2011 | EP2327715A1 Replikin peptides and uses thereof |
| 06/01/2011 | EP2327714A1 Prophylactic or therapeutic agent for influenza virus infection |
| 06/01/2011 | EP2327712A2 Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| 06/01/2011 | EP2327451A2 Method for detecting and inhibiting angiogenesis |
| 06/01/2011 | EP2327423A2 Human antibodies against human interleukin-22 (IL-22) |
| 06/01/2011 | EP2327422A1 Activin antagonists for diagnosis and therapy of diseases associated with fibrosis |
| 06/01/2011 | EP2327421A1 Stabilized liquid anti-RSV antibody formulations |
| 06/01/2011 | EP2327420A2 Monoparaimmunity inducers based on attenuated rabbit myxoma viruses |
| 06/01/2011 | EP2327419A1 Microneedle device, and method for enhancing the efficacy of influenza vaccine by using microneedle devive |
| 06/01/2011 | EP2327418A1 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from other viruses |
| 06/01/2011 | EP2327417A2 Identification of surface-associated antigens for tumour diagnosis and therapy |
| 06/01/2011 | EP2327413A1 Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use |
| 06/01/2011 | EP2326718A1 Inhbb epitope peptides and vaccines containing the same |
| 06/01/2011 | EP2326671A1 Lps based vaccines |
| 06/01/2011 | EP2326668A1 Anti-il-12/il-23 antibodies |
| 06/01/2011 | EP2326661A1 Synthetic peptides corresponding to overlapping neutralizing determinants in the cbd1 epitope induce broadly neutralizing antibodies. |
| 06/01/2011 | EP2326347A2 Targeting pathogenic monocytes |
| 06/01/2011 | EP2326346A1 Dock-and-lock (dnl) vaccines for cancer therapy |
| 06/01/2011 | EP2326345A2 Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling |
| 06/01/2011 | EP2326344A1 Salmonella vectored vaccines against chlamydia and methods of use |
| 06/01/2011 | EP2326315A1 Treatment of an autoimmune disease using il-18 antagonists |
| 06/01/2011 | EP2066344B1 Inactivated Poliovirus combination vaccine |
| 06/01/2011 | EP2015775B1 Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
| 06/01/2011 | EP1608307B1 An antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
| 06/01/2011 | EP1537419B1 Test for CD16-mediated ADCC efficacy of monoclonal or polyclonal antibodies |
| 06/01/2011 | EP1517987B1 Cotton rat lung cells for virus culture |
| 06/01/2011 | EP1259265B1 Nucleic acid formulations for gene delivery |
| 06/01/2011 | EP1073759B1 Recombinant virus expressing foreign dna encoding feline cd80, feline cd28, feline ctla-4 or feline cd86 and uses thereof |
| 06/01/2011 | DE102009047243A1 Monospezifische Polypeptidreagenzien Monospecific Polypeptidreagenzien |
| 06/01/2011 | CN1997392B Neisseria meningitidis igtB LOS as adjuvant |
| 06/01/2011 | CN1982338B Neutralized monoclone antibody 4C13 of antiricin, its production and use |
| 06/01/2011 | CN1805755B Therapeutic use of anti- CS1 antibodies |
| 06/01/2011 | CN102083984A Cynomolgus toll-like receptor 3 |
| 06/01/2011 | CN102083860A Antibodies to IL-6 and their uses |
| 06/01/2011 | CN102083853A Fusion proteins and their use in the diagnosis and treatment of leishmaniasis |
| 06/01/2011 | CN102083499A Combination therapy of a type II anti-CD20 antibody with a proteasome inhibitor |
| 06/01/2011 | CN102083465A Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| 06/01/2011 | CN102083464A Cytotoxic immunoglobulin |
| 06/01/2011 | CN102083463A Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant |
| 06/01/2011 | CN102083462A Lentiviral gene transfer vectors and their medicinal applications |
| 06/01/2011 | CN102083461A Potent conjugates and hydrophilic linkers |
| 06/01/2011 | CN102083460A Cysteine engineered antibodies for site-specific conjugation |